記住我
More aggressive multimodality treatment for this aggressive disease seems warranted to improve outcomes.3 Adding neoadjuvant or adjuvant RT, with or without hyperthermia, might already improve local recurrence-free survival.2,4 Moreover, strategies to include neoadjuvant or adjuvant systemic treatment such as paclitaxel in this setting seems the next step to improve distant metastases-free survival.5 Preferably, this should be done in a prospective study, although this might be difficult for a rare cancer like cAS. Therefore, the next best could be to collect real-world evidence from specialized sarcoma centers to learn how to improve treatment of this devastating disease.
留言 (0)